Atherosclerosis, a slowly progressing inflammatory disease, is characterized by the presence of monocyte‐derived macrophages. Interventions targeting the inflammatory characteristics of atherosclerosis hold promising potential. Although interleukin (IL)‐10 is widely acknowledged for its anti‐inflammatory effects, systemic administration of IL‐10 has limitations due to its short half‐life and significant systemic side effects. In this study, we aimed to investigate the effectiveness of an approach designed to overexpress IL‐10 in macrophages and subsequently introduce these genetically modified cells into ApoE−/− mice to promote atherosclerosis regression. We engineered RAW264.7 cells to overexpress IL‐10 (referred to as IL‐10M) using lentivirus vectors. The IL‐10M exhibited robust IL‐10 secretion, maintained phagocytic function, improved mitochondrial membrane potentials, reduced superoxide production and showed a tendency toward the M2 phenotype when exposed to inflammatory stimuli. IL‐10M can selectively target plaques in ApoE−/− mice and has the potential to reduce plaque area and necrotic core at both early and late stages of plaque progression. Moreover, there was a significant reduction in MMP9, a biomarker associated with plaque rupture, in IL‐10M‐treated plaques from both the early and late intervention groups. Additionally, the administration of IL‐10M showed no obvious side effects. This study serves as proof that cell therapy based on anti‐inflammatory macrophages might be a promising strategy for the intervention of atherosclerosis.
{"title":"Macrophages overexpressing interleukin‐10 target and prevent atherosclerosis: Regression of plaque formation and reduction in necrotic core","authors":"Mingyi Wang, Shanshan Zhou, Yingyun Hu, Wei Tong, Hao Zhou, Mingrui Ma, Xingxuan Cai, Zhengbin Zhang, Luo Zhang, Yundai Chen","doi":"10.1002/btm2.10717","DOIUrl":"https://doi.org/10.1002/btm2.10717","url":null,"abstract":"Atherosclerosis, a slowly progressing inflammatory disease, is characterized by the presence of monocyte‐derived macrophages. Interventions targeting the inflammatory characteristics of atherosclerosis hold promising potential. Although interleukin (IL)‐10 is widely acknowledged for its anti‐inflammatory effects, systemic administration of IL‐10 has limitations due to its short half‐life and significant systemic side effects. In this study, we aimed to investigate the effectiveness of an approach designed to overexpress IL‐10 in macrophages and subsequently introduce these genetically modified cells into ApoE<jats:sup>−/−</jats:sup> mice to promote atherosclerosis regression. We engineered RAW264.7 cells to overexpress IL‐10 (referred to as IL‐10M) using lentivirus vectors. The IL‐10M exhibited robust IL‐10 secretion, maintained phagocytic function, improved mitochondrial membrane potentials, reduced superoxide production and showed a tendency toward the M2 phenotype when exposed to inflammatory stimuli. IL‐10M can selectively target plaques in ApoE<jats:sup>−/−</jats:sup> mice and has the potential to reduce plaque area and necrotic core at both early and late stages of plaque progression. Moreover, there was a significant reduction in MMP9, a biomarker associated with plaque rupture, in IL‐10M‐treated plaques from both the early and late intervention groups. Additionally, the administration of IL‐10M showed no obvious side effects. This study serves as proof that cell therapy based on anti‐inflammatory macrophages might be a promising strategy for the intervention of atherosclerosis.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142236199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to “Self‐assembly of PEG–PPS polymers and LL‐37 peptide nanomicelles improves the oxidative microenvironment and promotes angiogenesis to facilitate chronic wound healing”","authors":"","doi":"10.1002/btm2.10718","DOIUrl":"https://doi.org/10.1002/btm2.10718","url":null,"abstract":"","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily R. Rhodes, Nicole B. Day, Emma C. Aldrich, C. Wyatt Shields, Kayla G. Sprenger
Polymeric micro‐ and nanoparticles are useful vehicles for delivering cytokines to diseased tissues such as solid tumors. Double emulsion solvent evaporation is one of the most common techniques to formulate cytokines into vehicles made from hydrophobic polymers; however, the liquid–liquid interfaces formed during emulsification can greatly affect the stability and therapeutic performance of encapsulated cytokines. To develop more effective cytokine‐delivery systems, a clear molecular understanding of the interactions between relevant proteins and solvents used in the preparation of such particles is needed. We utilized an integrated computational and experimental approach for studying the governing mechanisms by which interleukin‐12 (IL‐12), a clinically relevant cytokine, is protected from denaturation by albumin, a common stabilizing protein, at an organic‐aqueous solvent interface formed during double emulsification. We investigated protein–protein interactions between human (h)IL‐12 and albumin and simulated these components in pure water, dichloromethane (DCM), and along a water/DCM interface to replicate the solvent regimes formed during double emulsification. We observed that (i) hIL‐12 experiences increased structural deviations near the water/DCM interface, and (ii) hIL‐12 structural deviations are reduced in the presence of albumin. Experimentally, we found that hIL‐12 bioactivity is retained when released from particles in which albumin is added to the aqueous phase in molar excess to hIL‐12 and sufficient time is allowed for albumin‐hIL‐12 binding. Findings from this work have implications in establishing design principles to enhance the stability of cytokines and other unstable proteins in particles formed by double emulsification for improved stability and therapeutic efficacy.
{"title":"Elucidating the role of carrier proteins in cytokine stabilization within double emulsion‐based polymeric nanoparticles","authors":"Emily R. Rhodes, Nicole B. Day, Emma C. Aldrich, C. Wyatt Shields, Kayla G. Sprenger","doi":"10.1002/btm2.10722","DOIUrl":"https://doi.org/10.1002/btm2.10722","url":null,"abstract":"Polymeric micro‐ and nanoparticles are useful vehicles for delivering cytokines to diseased tissues such as solid tumors. Double emulsion solvent evaporation is one of the most common techniques to formulate cytokines into vehicles made from hydrophobic polymers; however, the liquid–liquid interfaces formed during emulsification can greatly affect the stability and therapeutic performance of encapsulated cytokines. To develop more effective cytokine‐delivery systems, a clear molecular understanding of the interactions between relevant proteins and solvents used in the preparation of such particles is needed. We utilized an integrated computational and experimental approach for studying the governing mechanisms by which interleukin‐12 (IL‐12), a clinically relevant cytokine, is protected from denaturation by albumin, a common stabilizing protein, at an organic‐aqueous solvent interface formed during double emulsification. We investigated protein–protein interactions between human (h)IL‐12 and albumin and simulated these components in pure water, dichloromethane (DCM), and along a water/DCM interface to replicate the solvent regimes formed during double emulsification. We observed that (i) hIL‐12 experiences increased structural deviations near the water/DCM interface, and (ii) hIL‐12 structural deviations are reduced in the presence of albumin. Experimentally, we found that hIL‐12 bioactivity is retained when released from particles in which albumin is added to the aqueous phase in molar excess to hIL‐12 and sufficient time is allowed for albumin‐hIL‐12 binding. Findings from this work have implications in establishing design principles to enhance the stability of cytokines and other unstable proteins in particles formed by double emulsification for improved stability and therapeutic efficacy.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clémentine Richter, Lorenz Latta, Daria Harig, Patrick Carius, Janick D. Stucki, Nina Hobi, Andreas Hugi, Paul Schumacher, Tobias Krebs, Alexander Gamrekeli, Felix Stöckle, Klaus Urbschat, Galia Montalvo, Franziska Lautenschläger, Brigitta Loretz, Alberto Hidalgo, Nicole Schneider‐Daum, Claus‐Michael Lehr
This study describes a complex human in vitro model for evaluating anti‐inflammatory drug response in the alveoli that may contribute to the reduction of animal testing in the pre‐clinical stage of drug development. The model is based on the human alveolar epithelial cell line Arlo co‐cultured with macrophages differentiated from the THP‐1 cell line, creating a physiological biological microenvironment. To mimic the three‐dimensional architecture and dynamic expansion and relaxation of the air‐blood‐barrier, they are grown on a stretchable microphysiological lung‐on‐chip. For validating the in vitro model, three different protocols have been developed to demonstrate the clinically established anti‐inflammatory effect of glucocorticoids to reduce certain inflammatory markers after different pro‐inflammatory stimuli: (1) an inflammation caused by bacterial LPS (lipopolysaccharides) to simulate an LPS‐induced acute lung injury measured best with cytokine IL‐6 release; (2) an inflammation caused by LPS at ALI (air‐liquid interface) to investigate aerosolized anti‐inflammatory treatment, measured with chemokine IL‐8 release; and (3) an inflammation with a combination of human inflammatory cytokines TNFα and IFNγ to simulate a critical cytokine storm leading to epithelial barrier disruption, where the eventual weakening or protection of the epithelial barrier can be measured. In all cases, the presence of macrophages appeared to be crucial to mediating inflammatory changes in the alveolar epithelium. LPS induction led to inflammatory changes independently of stretch conditions. Dynamic stretch, emulating breathing‐like mechanics, was essential for in vitro modeling of the clinically relevant outcome of epithelial barrier disruption upon TNFα/IFNγ‐induced inflammation.
{"title":"A stretchable human lung‐on‐chip model of alveolar inflammation for evaluating anti‐inflammatory drug response","authors":"Clémentine Richter, Lorenz Latta, Daria Harig, Patrick Carius, Janick D. Stucki, Nina Hobi, Andreas Hugi, Paul Schumacher, Tobias Krebs, Alexander Gamrekeli, Felix Stöckle, Klaus Urbschat, Galia Montalvo, Franziska Lautenschläger, Brigitta Loretz, Alberto Hidalgo, Nicole Schneider‐Daum, Claus‐Michael Lehr","doi":"10.1002/btm2.10715","DOIUrl":"https://doi.org/10.1002/btm2.10715","url":null,"abstract":"This study describes a complex human in vitro model for evaluating anti‐inflammatory drug response in the alveoli that may contribute to the reduction of animal testing in the pre‐clinical stage of drug development. The model is based on the human alveolar epithelial cell line Arlo co‐cultured with macrophages differentiated from the THP‐1 cell line, creating a physiological biological microenvironment. To mimic the three‐dimensional architecture and dynamic expansion and relaxation of the air‐blood‐barrier, they are grown on a stretchable microphysiological lung‐on‐chip. For validating the in vitro model, three different protocols have been developed to demonstrate the clinically established anti‐inflammatory effect of glucocorticoids to reduce certain inflammatory markers after different pro‐inflammatory stimuli: (1) an inflammation caused by bacterial LPS (lipopolysaccharides) to simulate an LPS‐induced acute lung injury measured best with cytokine IL‐6 release; (2) an inflammation caused by LPS at ALI (air‐liquid interface) to investigate aerosolized anti‐inflammatory treatment, measured with chemokine IL‐8 release; and (3) an inflammation with a combination of human inflammatory cytokines TNFα and IFNγ to simulate a critical cytokine storm leading to epithelial barrier disruption, where the eventual weakening or protection of the epithelial barrier can be measured. In all cases, the presence of macrophages appeared to be crucial to mediating inflammatory changes in the alveolar epithelium. LPS induction led to inflammatory changes independently of stretch conditions. Dynamic stretch, emulating breathing‐like mechanics, was essential for in vitro modeling of the clinically relevant outcome of epithelial barrier disruption upon TNFα/IFNγ‐induced inflammation.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to “Doxorubicin‐loaded nanoparticle coated with endothelial cells‐derived exosomes for immunogenic chemotherapy of glioblastoma”","authors":"","doi":"10.1002/btm2.10719","DOIUrl":"https://doi.org/10.1002/btm2.10719","url":null,"abstract":"","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Glioblastoma is a strong challenge in the worldwide field of central nervous system malignancies. GBM's inherent heterogeneity, along with the formation of an immunosuppressive tumor microenvironment, supports its resistance to current therapy methods. Immunotherapeutic methods have emerged as potential options in recent years. However, because of the inherent limits of traditional immunotherapeutic techniques innovative approaches are required. Advances in cut‐edge techniques provide a possible route for improving effector cell effectiveness. This review gives insight into the complicated immunosuppressive pathways in GBM, with a particular emphasis on CAR T/NK‐cell treatment as a potential achievement. Recognizing and addressing these concerns might open the way for more effective and focused glioblastoma therapies, providing hope for the future with the aim of improved outcomes for patients. In addition, this review presents valuable insights into the integration of nanotechnology into CAR T/NK cell therapy for enhanced efficiency of these personalized gene therapy products.
胶质母细胞瘤是世界范围内中枢神经系统恶性肿瘤领域的一个严峻挑战。胶质母细胞瘤固有的异质性以及免疫抑制性肿瘤微环境的形成，使其对目前的治疗方法产生了抗药性。近年来，免疫治疗方法已成为潜在的选择。然而，由于传统的免疫治疗技术存在固有的局限性，因此需要创新的方法。尖端技术的进步为提高效应细胞的有效性提供了可能的途径。本综述深入探讨了 GBM 复杂的免疫抑制途径，并特别强调了 CAR T/NK 细胞治疗这一潜在成果。认识并解决这些问题可能会为更有效、更有针对性的胶质母细胞瘤疗法开辟道路，为未来带来希望，从而改善患者的预后。此外，本综述还就如何将纳米技术融入 CAR T/NK 细胞疗法以提高这些个性化基因治疗产品的效率提出了宝贵的见解。
{"title":"Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/NK cell therapy","authors":"Nasim Dana, Arezou Dabiri, Majed Bahri Najafi, Azadeh Rahimi, Sayed Mohammad Matin Ishaghi, Laleh Shariati, Minmin Shao, Assunta Borzacchiello, Ilnaz Rahimmanesh, Pooyan Makvandi","doi":"10.1002/btm2.10716","DOIUrl":"https://doi.org/10.1002/btm2.10716","url":null,"abstract":"Glioblastoma is a strong challenge in the worldwide field of central nervous system malignancies. GBM's inherent heterogeneity, along with the formation of an immunosuppressive tumor microenvironment, supports its resistance to current therapy methods. Immunotherapeutic methods have emerged as potential options in recent years. However, because of the inherent limits of traditional immunotherapeutic techniques innovative approaches are required. Advances in cut‐edge techniques provide a possible route for improving effector cell effectiveness. This review gives insight into the complicated immunosuppressive pathways in GBM, with a particular emphasis on CAR T/NK‐cell treatment as a potential achievement. Recognizing and addressing these concerns might open the way for more effective and focused glioblastoma therapies, providing hope for the future with the aim of improved outcomes for patients. In addition, this review presents valuable insights into the integration of nanotechnology into CAR T/NK cell therapy for enhanced efficiency of these personalized gene therapy products.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142100738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Epigenetics mechanisms play a significant role in human diseases by altering DNA methylation status, chromatin structure, and/or modifying histone proteins. By modulating the epigenetic status, the expression of genes can be regulated without any change in the DNA sequence itself. Epigenetic drugs exhibit promising therapeutic efficacy against several epigenetically originated diseases including several cancers, neurodegenerative diseases, metabolic disorders, cardiovascular disorders, and so forth. Currently, a considerable amount of research is focused on discovering new drug molecules to combat the existing research gap in epigenetic drug therapy. A novel and efficient delivery system can be established as a promising approach to overcome the drawbacks associated with the current epigenetic modulators. Therefore, formulating the existing epigenetic drugs with distinct encapsulation strategies in nanocarriers, including solid lipid nanoparticles, nanogels, bio‐engineered nanocarriers, liposomes, surface modified nanoparticles, and polymer–drug conjugates have been examined for therapeutic efficacy. Nonetheless, several epigenetic modulators are untouched for their therapeutic potential through different delivery strategies. This review provides a comprehensive up to date discussion on the research findings of various epigenetics mechanism, epigenetic modulators, and delivery strategies utilized to improve their therapeutic outcome. Furthermore, this review also highlights the recently emerged CRISPR tool for epigenome editing.
表观遗传学机制通过改变 DNA 甲基化状态、染色质结构和/或修饰组蛋白，在人类疾病中发挥着重要作用。通过调节表观遗传状态，可以在不改变 DNA 序列本身的情况下调节基因的表达。表观遗传药物对几种由表观遗传引起的疾病，包括几种癌症、神经退行性疾病、代谢紊乱、心血管疾病等具有良好的疗效。目前，大量研究都集中在发现新的药物分子上，以填补表观遗传药物治疗领域现有的研究空白。建立新颖高效的给药系统是克服现有表观遗传调节剂弊端的有效方法。因此，研究人员采用不同的封装策略将现有的表观遗传药物配制成纳米载体，包括固体脂质纳米颗粒、纳米凝胶、生物工程纳米载体、脂质体、表面修饰纳米颗粒和聚合物-药物共轭物，以研究其疗效。然而，还有一些表观遗传调节剂尚未通过不同的递送策略发挥其治疗潜力。本综述对各种表观遗传学机制、表观遗传学调节剂以及用于改善治疗效果的给药策略的研究成果进行了全面的最新讨论。此外，本综述还重点介绍了最近出现的用于表观基因组编辑的 CRISPR 工具。
{"title":"Targeting the epigenome with advanced delivery strategies for epigenetic modulators","authors":"Sonia Guha, Yogeswaran Jagadeesan, Murali Monohar Pandey, Anupama Mittal, Deepak Chitkara","doi":"10.1002/btm2.10710","DOIUrl":"https://doi.org/10.1002/btm2.10710","url":null,"abstract":"Epigenetics mechanisms play a significant role in human diseases by altering DNA methylation status, chromatin structure, and/or modifying histone proteins. By modulating the epigenetic status, the expression of genes can be regulated without any change in the DNA sequence itself. Epigenetic drugs exhibit promising therapeutic efficacy against several epigenetically originated diseases including several cancers, neurodegenerative diseases, metabolic disorders, cardiovascular disorders, and so forth. Currently, a considerable amount of research is focused on discovering new drug molecules to combat the existing research gap in epigenetic drug therapy. A novel and efficient delivery system can be established as a promising approach to overcome the drawbacks associated with the current epigenetic modulators. Therefore, formulating the existing epigenetic drugs with distinct encapsulation strategies in nanocarriers, including solid lipid nanoparticles, nanogels, bio‐engineered nanocarriers, liposomes, surface modified nanoparticles, and polymer–drug conjugates have been examined for therapeutic efficacy. Nonetheless, several epigenetic modulators are untouched for their therapeutic potential through different delivery strategies. This review provides a comprehensive up to date discussion on the research findings of various epigenetics mechanism, epigenetic modulators, and delivery strategies utilized to improve their therapeutic outcome. Furthermore, this review also highlights the recently emerged CRISPR tool for epigenome editing.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The endometrium, the inner lining of the uterus, assumes a crucial role in the female reproductive system. Disorders and injuries impacting the endometrium can lead to profound consequences, including infertility and compromised women's overall health. Recent advancements in stem cell research have opened new possibilities for the treatment and repair of endometrial issues. In the present study, we constructed a degradable hydrogel by loading adipose‐derived stem cells (ADSCs) and melanin nanoparticles (MNP). In vitro cell experiments validated the biocompatibility of the prepared hydrogels and their adeptness in encapsulating ADSCs. Subsequently, we explored the impact of hydrogel@ADSC@MNP constructs in the healing process of uterine injury in mice. The results indicated that hydrogel@ADSC@MNP could augment endometrial thickness and ameliorate endometrial interstitial fibrosis. The injured tissue adjacent to hydrogel@ADSC@MNP constructs exhibited higher levels of bFGF, IGF‐1, and VEGFA compared with the corresponding tissue in mice receiving hydrogel constructs alone or in the model group. Furthermore, the hydrogel@ADSC@MNP system enhanced the proliferative capabilities of uterine endometrial cells, facilitated microvasculature regeneration, and reinstated the endometrium's capacity to receive the embryos. Our findings strongly suggest that the hydrogel@ADSC@MNP system holds significant promise for repairing and regenerating damaged endometrium.
{"title":"A temperature responsive hydrogel encapsulated with adipose‐derived stem cells and melanin promotes repair and regeneration of endometrial injury","authors":"Ruigao Song, Chicheng Ma, Hongxia Li, Yu Cheng, Xianmei Cui, Zanhong Wang, Lijuan Huang, Chunying Song, Yukai Jing, Bing Cao, Lili Wang, Qing Tian, Xi Wang, Ruiping Zhang, Hanwang Zhang","doi":"10.1002/btm2.10714","DOIUrl":"https://doi.org/10.1002/btm2.10714","url":null,"abstract":"The endometrium, the inner lining of the uterus, assumes a crucial role in the female reproductive system. Disorders and injuries impacting the endometrium can lead to profound consequences, including infertility and compromised women's overall health. Recent advancements in stem cell research have opened new possibilities for the treatment and repair of endometrial issues. In the present study, we constructed a degradable hydrogel by loading adipose‐derived stem cells (ADSCs) and melanin nanoparticles (MNP). In vitro cell experiments validated the biocompatibility of the prepared hydrogels and their adeptness in encapsulating ADSCs. Subsequently, we explored the impact of hydrogel@ADSC@MNP constructs in the healing process of uterine injury in mice. The results indicated that hydrogel@ADSC@MNP could augment endometrial thickness and ameliorate endometrial interstitial fibrosis. The injured tissue adjacent to hydrogel@ADSC@MNP constructs exhibited higher levels of bFGF, IGF‐1, and VEGFA compared with the corresponding tissue in mice receiving hydrogel constructs alone or in the model group. Furthermore, the hydrogel@ADSC@MNP system enhanced the proliferative capabilities of uterine endometrial cells, facilitated microvasculature regeneration, and reinstated the endometrium's capacity to receive the embryos. Our findings strongly suggest that the hydrogel@ADSC@MNP system holds significant promise for repairing and regenerating damaged endometrium.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141994338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qiang Chen, Ku‐Geng Huo, Sheng‐Min Ji, Shu‐De Pang, Tian‐Ying Sun, Yi Niu, Zi‐Hao Jiang, Peng Zhang, Shu‐Xin Han, Jin‐Yao Li
Messenger RNA (mRNA) has emerged as a promising therapeutic strategy for various diseases, including cancer, infectious diseases, and genetic disorders. The mRNA‐based therapeutics have gained significant attention due to their ability to regulate targeted cells, activate immune cells, and avoid potential risks associated with DNA‐based technology. However, the clinical application of mRNA in cancer therapy is hindered by the instability of RNA, physiological barriers, and the risk of immunogenic hurdles. To overcome these challenges and ensure the safe delivery of mRNA therapeutics to target sites, nanoparticle‐based delivery systems have been explored as potential tools in vitro and in vivo applications. This review provides a comprehensive overview of the current status of mRNA therapy, discussing its advantages and limitations, delivery strategies and materials, as well as applications in different fields. By exploring these aspects, the researcher can gain a more complete understanding of the current state, prospects, and challenges of mRNA technologies.
{"title":"Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles","authors":"Qiang Chen, Ku‐Geng Huo, Sheng‐Min Ji, Shu‐De Pang, Tian‐Ying Sun, Yi Niu, Zi‐Hao Jiang, Peng Zhang, Shu‐Xin Han, Jin‐Yao Li","doi":"10.1002/btm2.10713","DOIUrl":"https://doi.org/10.1002/btm2.10713","url":null,"abstract":"Messenger RNA (mRNA) has emerged as a promising therapeutic strategy for various diseases, including cancer, infectious diseases, and genetic disorders. The mRNA‐based therapeutics have gained significant attention due to their ability to regulate targeted cells, activate immune cells, and avoid potential risks associated with DNA‐based technology. However, the clinical application of mRNA in cancer therapy is hindered by the instability of RNA, physiological barriers, and the risk of immunogenic hurdles. To overcome these challenges and ensure the safe delivery of mRNA therapeutics to target sites, nanoparticle‐based delivery systems have been explored as potential tools in vitro and in vivo applications. This review provides a comprehensive overview of the current status of mRNA therapy, discussing its advantages and limitations, delivery strategies and materials, as well as applications in different fields. By exploring these aspects, the researcher can gain a more complete understanding of the current state, prospects, and challenges of mRNA technologies.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141991784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to “Activation of NR1H3 attenuates the severity of septic myocardial injury by inhibiting NLRP3 inflammasome”","authors":"","doi":"10.1002/btm2.10707","DOIUrl":"https://doi.org/10.1002/btm2.10707","url":null,"abstract":"","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141986248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：